Webcast ImageWebcast
Cidara Therapeutics, Inc. at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (Replay)
09/28/16 at 3:05 p.m. ET
Cidara Therapeutics, Inc. at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Wednesday, September 28, 2016 3:05 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD101 topical is the first and only agent of its class being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$11.15 - 0.514.37%57,236
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
09/29/16 4:00 p.m. ET
Refresh quote


Stock chart for: CDTX.O.  Currently trading at $11.15 with a 52 week high of $18.07 and a 52 week low of $9.48.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources